Role of Hypoxia in Diffuse Large B-Cell Lymphoma: Metabolic Repression and Selective Translation of HK2 Facilitates Development of DLBCL

Scientific Reports - United Kingdom
doi 10.1038/s41598-018-19182-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Ets1 Positively Regulates Faim3 in Activated B Cell-Like (Abc) Diffuse Large B Cell Lymphoma (Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Simultaneous Diffuse Large B-Cell Lymphoma (Dlbcl) and Follicular Lymphoma (Fl) at the Diagnosis Has Similar Outcome as DLBCL

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma (Dlbcl): A Large Population-Based Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Diffuse Large B-Cell Lymphoma

2020English

Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Assessment Index of Clinical Transformation From Follicular Lymphoma (Fl) to Diffuse Large B-Cell Lymphoma (Dlbcl) in the Rituximab Era

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Case Report of Unusually Long Lag Time Between Immunotactoid Glomerulopathy (Itg) Diagnosis and Diffuse Large B-Cell Lymphoma (DLBCL) Development

BMC Nephrology
Nephrology
2016English

Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma

Seminars in Diagnostic Pathology
Forensic MedicinePathology
2011English

66. Identification and Characterization of a B Cell Aptamer That Targets Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Myelogenous Leukemia (CML)

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy